Literature DB >> 11187541

Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease.

M Berres1, A U Monsch, F Bernasconi, B Thalmann, H B Stähelin.   

Abstract

The diagnosis of early stage dementia is a highly complex process involving not only a somatic examination but also a neuropsychological assessment of the patient's cognitive capability. The American 'Consortium to Establish a Registry for Alzheimer's Disease' (CERAD) has proposed a set of tests in English which has been translated into German. This paper presents the statistical methodology applied to determine normal ranges adjusted for demographic variables for the German CERAD neuropsychological assessment battery (CERAD-NAB). The study population consists of participants of the Basel Study on the Elderly (Project BASEL) which aims at identifying preclinical markers of Alzheimer's disease. The normative sample has been defined by carefully excluding potentially relevant medical history and concomitant diseases and consists of 617 participants which are between 53 and 92 years old. Test results should be adjusted for gender, age, and years of education. For this purpose, a set of linear models including these predictors and subsets of their interactions and squares was evaluated for all 11 test scores derived from the CERAD-NAB battery. Model selection was based on the PRESS (predicted residual sum of squares) statistic. Although a strict application of this criterion selected 6 different models, a slight compromise allowed to fit all test scores by two models. In several tests of the CERAD-NAB many participants achieve maximal scores. Residuals of such test scores are heavily skewed. An arcsine transformation has been tuned to the data, so that residuals are close to a normal distribution, at least for residuals in the lower quartile which is relevant in diagnosing cognitive impairment. Test results are finally presented as z-scores which can be easily compared to a standard normal distribution. The evaluation of the CERAD-NAB is implemented on the Internet and in an Excel application.

Entities:  

Mesh:

Year:  2000        PMID: 11187541

Source DB:  PubMed          Journal:  Stud Health Technol Inform        ISSN: 0926-9630


  45 in total

1.  Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study.

Authors:  Y Likitjaroen; T Meindl; U Friese; M Wagner; K Buerger; H Hampel; S J Teipel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-05       Impact factor: 5.270

2.  [CERAD-NP battery: Age-, gender- and education-specific reference values for selected subtests. Results of the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe)].

Authors:  T Luck; S G Riedel-Heller; B Wiese; J Stein; S Weyerer; J Werle; H Kaduszkiewicz; M Wagner; E Mösch; T Zimmermann; W Maier; H Bickel; H van den Bussche; F Jessen; A Fuchs; M Pentzek
Journal:  Z Gerontol Geriatr       Date:  2009-07-30       Impact factor: 1.281

3.  The role of memory-related gene polymorphisms, KIBRA and CLSTN2, on replicate memory assessment in the elderly.

Authors:  N Sédille-Mostafaie; C Sebesta; K R Huber; S Zehetmayer; S Jungwirth; K H Tragl; P Fischer; W Krugluger
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

4.  The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study.

Authors:  Stefan J Teipel; Thomas Meindl; Lea Grinberg; Michel Grothe; Jose L Cantero; Maximilian F Reiser; Hans-Jürgen Möller; Helmut Heinsen; Harald Hampel
Journal:  Hum Brain Mapp       Date:  2010-07-29       Impact factor: 5.038

5.  FAB-D: German version of the Frontal Assessment Battery.

Authors:  Thomas Benke; Elfriede Karner; Margarete Delazer
Journal:  J Neurol       Date:  2013-05-07       Impact factor: 4.849

6.  Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.

Authors:  Timo Grimmer; Susanne Tholen; Behrooz H Yousefi; Panagiotis Alexopoulos; Annette Förschler; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Robert Perneczky; Christian Sorg; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

7.  Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus.

Authors:  Stefan J Teipel; Wilhelm Flatz; Nibal Ackl; Michel Grothe; Ingo Kilimann; Arun L W Bokde; Lea Grinberg; Edson Amaro; Vanja Kljajevic; Eduardo Alho; Christina Knels; Anne Ebert; Helmut Heinsen; Adrian Danek
Journal:  Psychiatry Res       Date:  2013-12-06       Impact factor: 3.222

8.  Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort.

Authors:  I Blasko; M Hinterberger; G Kemmler; S Jungwirth; W Krampla; T Leitha; K Heinz Tragl; P Fischer
Journal:  J Nutr Health Aging       Date:  2012-08       Impact factor: 4.075

9.  Regional networks underlying interhemispheric connectivity: an EEG and DTI study in healthy ageing and amnestic mild cognitive impairment.

Authors:  Stefan J Teipel; Oliver Pogarell; Thomas Meindl; Olaf Dietrich; Djyldyz Sydykova; Ulrike Hunklinger; Bea Georgii; Christoph Mulert; Maximilian F Reiser; Hans-Jürgen Möller; Harald Hampel
Journal:  Hum Brain Mapp       Date:  2009-07       Impact factor: 5.038

10.  Population normative data for the 10/66 Dementia Research Group cognitive test battery from Latin America, India and China: a cross-sectional survey.

Authors:  Ana Luisa Sosa; Emiliano Albanese; Martin Prince; Daisy Acosta; Cleusa P Ferri; Mariella Guerra; Yueqin Huang; K S Jacob; Juan Llibre de Rodriguez; Aquiles Salas; Fang Yang; Ciro Gaona; At Joteeshwaran; Guillermina Rodriguez; Gabriela Rojas de la Torre; Joseph D Williams; Robert Stewart
Journal:  BMC Neurol       Date:  2009-08-26       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.